Diagnosis and Management of Dedifferentiated Liposarcoma: A Multidisciplinary Task Force Podcast

STATEMENT OF NEED

Dedifferentiated liposarcoma (DDLPS) is an aggressive subtype of soft tissue sarcoma. Detection of MDM2 and/or CDK4 amplification distinguishes DDLPS from other types of undifferentiated sarcomas. Diagnosis of DDLPS remains challenging due to its complex karyotypes, quantitative genomic profiles, and pleomorphic pathological features (Nishio et al, 2021; Shen et al, 2022). Currently, surgical resection with or without radiation is the mainstay of treatment for localized disease, and anthracycline-based therapy is a standard first-line treatment for advanced disease. Numerous novel therapies are currently under investigation, including CDK4/6 inhibitors, MDM2-p53 pathway inhibitors, and immunotherapies, with the potential to transform the treatment landscape for DDLPS (Nishio et al, 2021). Due to the complex management of DDLPS, collaboration of the multidisciplinary health care team, including medical oncologists, surgical oncologists, radiation oncologists, and pathologists, is crucial. This Dedifferentiated Liposarcoma Task Force podcast will provide a consensus opinion on the optimal diagnosis, treatment, and management of this disease. It features perspectives from Task Force co-chairs Richard F. Riedel, MD, Associate Professor in the Division of Medical Oncology at Duke University Medical Center, and Candace L. Haddox, MD, Physician at Dana-Farber Cancer Institute and Instructor in Medicine at Harvard Medical School.

TARGET AUDIENCE

Medical oncologists, surgical oncologists, pathologists, nurse practitioners, physician assistants/associates and other healthcare professionals involved in the treatment of patients with soft tissue sarcoma.

Upon completion of this activity, participants should be able to

• Summarize the key clinical, histopathologic, and genomic characteristics that make dedifferentiated liposarcoma unique from other soft tissue sarcoma subtypes
• Assess the benefits and limitations of current molecular testing methodologies for the characterization of soft tissue sarcomas
• Appreciate the role of a multimodality approach in the management of localized dedifferentiated liposarcoma, as well as the current systemic therapy landscape for patients with advanced disease
• Evaluate potential emerging therapies, including MDM2-p53 pathway inhibitors, CDK4/6 inhibitors, and immunotherapeutic approaches, for the treatment of dedifferentiated liposarcoma

JOINTLY ACCREDITED PROVIDER

In support of improving patient care, i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIANS

i3 Health designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.

Physician Assistants/Associates

i3 Health has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 11/21/25. PAs should only claim credit commensurate with the extent of their participation. 

Nurse Practitioners

The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES

i3 Health endorses the standards of the ACCME that require everyone in a position to control the content of a CME activity to disclose all financial relationships with ineligible companies that are related to the content of the CME activity. CME activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when an individual has an opportunity to affect CME content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.

Relevant financial relationships exist between the following individuals and ineligible companies:

The i3 Health planners, reviewers, and managers have nothing to disclose.

Richard F. Riedel, MD, discloses that he has received grants/research support from Aadi Bioscience, AROG, Ayala, BioAtla, Blueprint, Cogent, Daiichi-Sankyo, Deciphera, GlaxoSmithKline, InhibRx, NanoCarrier, Oncternal, PTC Therapeutics, SARC, SpringWorks, TRACON, and Trillium; and that he has served as a consultant or on an advisory board/panel for Aadi Bioscience, Adaptimmune, Bayer, Blueprint, Boehringer Inhelheim, Daiichi-Sankyo, Decipheral, GlaxoSmithKline, NanoCarrier, and SpringWorks.

Candace L. Haddox, MD, discloses that she has served as a consultant or on an advisory/board panel for Aadi Bioscience; and that she has received grants/research support from Aadi Bioscience, EMD Serono, Cogent, HiFiBio, Roche, and Tango Therapeutics.

i3 Health has mitigated all relevant financial relationships.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, participants must listen to the podcast and submit a completed evaluation at the end of the activity.

TECHNOLOGY REQUIREMENTS FOR VIRTUAL CME ACTIVITIES

For virtual (asynchronous, archived live, home study; synchronous webinars) CME activities, include access to system requirements:

• The Internet browser(s) supported and minimum versions of each required by the learner to complete the online activity.
• The minimum memory, storage, processor, and Internet speeds require by the learner to complete the online activity.

UNAPPROVED USE DISCLOSURE

i3 Health requires CME faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.

This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

DISCLAIMER

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a health care provider relative to diagnostic and treatment options of a specific patient’s medical condition.

COMMERCIAL SUPPORT

This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.